<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467879</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04467879</nct_id>
  </id_info>
  <brief_title>A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients</brief_title>
  <official_title>A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zona Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zona Health, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded randomized controlled study assessing the effectiveness of isometric
      handgrip therapy. Approximately 230 patients who present with a Systolic Blood Pressure
      reading of ≤ 149mmHg and who have not taken antihypertensive medication for more than 30 days
      will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the effectiveness of isometric handgrip therapy in patients
      diagnosed with prehypertension or hypertension who are not at target BP and who have not
      taken antihypertensive medication for more than 30 days before study entry. The
      investigational plan examines blood pressure (BP) changes in up to 230 patients randomized to
      either the Zona Plus device (i.e., the device proposed for marketing), or to a Placebo &quot;sham&quot;
      device (which is intentionally calibrated for a &quot;weaker grip&quot; device).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, double-blinded, randomized, controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure to Day 70 ± 2 Days</measure>
    <time_frame>Change from Baseline to Day 70 ±2 Days</time_frame>
    <description>Comparative assessment in the change from Baseline in seated cuff Systolic Blood Pressure after ten(10) weeks of treatment between patients treated with the Zona Plus nominal device (&quot;stronger grip&quot;) and patients treated with the Placebo control device (&quot;weaker grip&quot;). A reduction in Systolic Blood ≥ 5 Preassure after 10 weeks of treatment is considered to be a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure to Day 70 ± 2 Days</measure>
    <time_frame>Change from Baseline to Day 70 ±2 Days</time_frame>
    <description>Comparative assessment of the change from Baseline in seated cuff Diastolic Blood Pressure after 10 weeks of treatment between patients treated with the Zona Plus nominal device (&quot;stronger grip&quot;) and patients treated with the Placebo control device (&quot;weaker grip&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in Systolic Blood Pressure reduction at Day 70 ± 2 Days</measure>
    <time_frame>Change from Baseline to Day 70 ± 2 Days</time_frame>
    <description>Comparative assessment in the percentage of patients who achieve a clinically significant Systolic Blood Pressure reduction (defined as ≥ 5 mmHg) at Day 70 ± 2 Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in Diastolic Blood Pressure reduction at Day 70 ± 2 Days</measure>
    <time_frame>Change from Baseline to Day 70 ± 2 Days</time_frame>
    <description>Comparative assessment in the percentage of patients who achieve a clinically significant Diastolic Blood Pressure reduction (defined as ≥3 mmHg) at Day 70 ± 2 Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days</measure>
    <time_frame>Change from Baseline to Day 160 ± 4 Days</time_frame>
    <description>Comparative assessment in change from Baseline in the seated cuff Systolic Blood Pressure after 6 months Day 160 ± 4 of treatment between patients treated with the Zona Plus nominal device and patients treated with the Placebo control device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days</measure>
    <time_frame>Change from Baseline to Day 160 ± 4 Days</time_frame>
    <description>Comparative assessment in change from Baseline in the seated cuff Diastolic Blood Pressure after 6 months Day 160 ± 4 Days of treatment between patients treated with the Zona Plus nominal device and patients treated with the Placebo control device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days</measure>
    <time_frame>Change from Baseline to Day 160 ± 4 Days</time_frame>
    <description>Comparative assessment in the percentage of patients who achieve a clinically significant Systolic Blood Pressure reduction (defined as ≥ 5 mmHg) at Day 160 ± 4 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days</measure>
    <time_frame>Change from Baseline to Day 160 ± 4 Days</time_frame>
    <description>Comparative assessment in the percentage of patients who achieve a clinically significant Diastolic Blood Pressure reduction defined as ≥3 mmHg at Day 160 ± 4 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Heart Rate between Zona Plus nominal device and Placebo controlled device</measure>
    <time_frame>Change from Baseline to Day 160 ± 4 Days</time_frame>
    <description>The Heart Rate (HR) will be recorded and compared between the Zona Plus nominal device and the Placebo control device treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Hypertension, Systolic</condition>
  <arm_group>
    <arm_group_label>Zona Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using the Zona Plus device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment(the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip,or rest,session between each isometric routine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Device</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using the Zona Placebo Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment(the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip,or rest,session between each isometric routine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zona Plus</intervention_name>
    <description>Zona Plus</description>
    <arm_group_label>Zona Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Device</intervention_name>
    <description>Control Device</description>
    <arm_group_label>Control Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female of any ethnicity between 18 and 80 years of age

          -  Diagnosed with prehypertension or hypertension and verified during the Baseline visit

          -  Non-use of antihypertensive medication for ≥30 prior to screening

          -  Currently not taking any antihypertensive medications or decline to take any
             antihypertensive medications(e.g., diuretic, angiotensin-converting enzyme inhibitor
             (ACEI), angiotensin II receptor blocker (ARB), ] beta-blocker (BB), renin inhibitor
             (RI), calcium channel blocker (CCB) or alpha-adrenergic agonist (clonidine))

          -  Sufficient vision with the patient able to see the screen prompts on the device,
             sufficient hearing with the patient able to hear the device audio prompts, sufficient
             hand strength (demonstrated by a maximum voluntary contraction equaling 35 units of
             force in both hands measured by the device)

          -  Baseline Blood Pressure measurements collected and study device training completed
             during the Baseline visit

          -  Non-use of medications and over the counter (OTC)supplement regimen related to
             hypertension throughout the study duration

          -  Only one patient per household can participate in the study, eliminating the potential
             of unblinding

          -  Able to comply with study procedures and agrees to complete all required study visits
             and associated activities

          -  Ability to give written informed consent in either English, Spanish or French •≤149
             mmHg, Systolic Blood Pressure wherein patients who present with Systolic Blood
             Pressure readings ≥140 mmHg will receive heightened monitoring throughout the first
             month of the study

        Exclusion Criteria

          -  Pregnant or not using adequate contraception

          -  Blood Pressure ≥150 mmHg (systolic) and/or &gt;90 mmHg (diastolic)

          -  History of heart failure

          -  Hospitalization due to a hypertensive emergency, with impending or progressive target
             organ dysfunction (i.e., renal dysfunction, left ventricular hypertrophy or CNS
             involvement) within the past six (6) months

             •&gt;10 mmHg difference in Systolic Blood Pressure between the right and left arms
             collected during screening

          -  Unstable Blood Pressure, defined as &gt;5 mmHg variance between any two (2) consecutive
             weekly readings (with a maximum of four (4) attempts) to determine a baseline BP
             measurement

          -  Arm circumference greater than 45cm

          -  Acute illness, infection, or inflammation

          -  Unstable cardiovascular disorder, such as MI, unstable angina, significant arrhythmia,
             stroke, or TIA within the last six (6)months, or other serious comorbidity impacting
             life expectancy to &lt; than a 1 year

          -  Rest or exertional angina pectoris in the previous six (6) months

          -  History of solid organ transplant

          -  Secondary form of hypertension (HTN) etiology, including but not limited to primary
             aldosteronism, chronic steroid therapy and Cushing syndrome, pheochromocytoma, aorta
             coarctation or untreated thyroid or parathyroid disease

          -  Concurrent participation in an investigational clinical study that has not completed
             the follow-up period or planned participation in another study within the next six(6)
             months

          -  Any condition or personal circumstance that, in the judgment of the investigator,
             might interfere with the collection of complete, good quality data or the completion
             of the research study

          -  Currently own or have owned another Zona Plus device and are,or have been,voluntarily
             performing the isometric handgrip activities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanetza Camacho, BS</last_name>
    <phone>786-925-3579</phone>
    <email>yzassoc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Crystal Biomedical Researc, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Marti, MD</last_name>
      <phone>305-671-3686</phone>
      <email>gmanager@medcra.com</email>
    </contact>
    <investigator>
      <last_name>Angel Rico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Top Endocrine Focused Research Corp</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Marti</last_name>
      <phone>605-671-3686</phone>
      <email>gmanager@medcra.com</email>
    </contact>
    <investigator>
      <last_name>Lysette Iglesias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milagros Taveras</last_name>
      <phone>305-631-6704</phone>
      <phone_ext>112</phone_ext>
      <email>mtaveras@SuncoastResearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark E Kutner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Healthy Life Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Marti</last_name>
      <phone>305-671-3686</phone>
      <email>gmanager@medcra.com</email>
    </contact>
    <investigator>
      <last_name>Hilda Brito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bio-Medical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Marti, MD</last_name>
      <phone>305-671-3686</phone>
      <email>gmanager@medcra.com</email>
    </contact>
    <investigator>
      <last_name>Lilia Roque Guerrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-indication-drug-labeling-cardiovascular-outcome-claims</url>
    <description>Drug Labeling for Cardiovascular Outcome Claims</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073147.pdf</url>
    <description>Principles for ClinicalEvaluation ofNew Antihypertensive Drugs.</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf</url>
    <description>The Seventh Report of the Joint National Committee on Prevention, Detection,Evaluation, and Treatment of High Blood Pressure</description>
  </link>
  <reference>
    <citation>Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. Erratum in: Circulation. 2011 Feb 15;123(6):e240. Circulation. 2011 Oct 18;124(16):e426.</citation>
    <PMID>21160056</PMID>
  </reference>
  <reference>
    <citation>ACSM's Guidelines for Exercise Testing and Prescription, 7thedition, May 2005</citation>
  </reference>
  <reference>
    <citation>Al-Khatib SM, Califf RM, Hasselblad V, Alexander JH, McCrory DC, Sugarman J. Medicine. Placebo-controls in short-term clinical trials of hypertension. Science. 2001 Jun 15;292(5524):2013-5. Review.</citation>
    <PMID>11408643</PMID>
  </reference>
  <reference>
    <citation>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97. Erratum in: JAMA 2003 Jan 8;289(2):178. JAMA. 2004 May 12;291(18):2196.</citation>
    <PMID>12479763</PMID>
  </reference>
  <reference>
    <citation>Bakke EF, Hisdal J, Kroese AJ, Jørgensen JJ, Stranden E. Blood pressure response to isometric exercise in patients with peripheral atherosclerotic disease. Clin Physiol Funct Imaging. 2007 Mar;27(2):109-15.</citation>
    <PMID>17309531</PMID>
  </reference>
  <reference>
    <citation>Balasubramanian V, Mann S, Millar-Craig MW, Raftery EB. Effect of labetalol in hypertension during exercise and postural changes. Br J Clin Pharmacol. 1979 Apr;8 Suppl 2:95S-100S. doi: 10.1111/j.1365-2125.1979.tb04761.x.</citation>
    <PMID>26635176</PMID>
  </reference>
  <reference>
    <citation>Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacoucière Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension. 2001 Jan;37(1):12-18.</citation>
    <PMID>11208750</PMID>
  </reference>
  <reference>
    <citation>Boutcher SH, Stocker D. Cardiovascular responses to light isometric and aerobic exercise in 21- and 59-year-old males. Eur J Appl Physiol Occup Physiol. 1999 Aug;80(3):220-6.</citation>
    <PMID>10453924</PMID>
  </reference>
  <reference>
    <citation>Buck C, Donner AP. Isometric occupational exercise and the incidence of hypertension. J Occup Med. 1985 May;27(5):370-2.</citation>
    <PMID>4009307</PMID>
  </reference>
  <reference>
    <citation>Chrysant SG. Current evidence on the hemodynamic and blood pressure effects of isometric exercise in normotensive and hypertensive persons. J Clin Hypertens (Greenwich). 2010 Sep;12(9):721-6. doi: 10.1111/j.1751-7176.2010.00328.x. Review.</citation>
    <PMID>20883233</PMID>
  </reference>
  <reference>
    <citation>Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404.</citation>
    <PMID>12461301</PMID>
  </reference>
  <reference>
    <citation>Eguchi K, Yacoub M, Jhalani J, Gerin W, Schwartz JE, Pickering TG. Consistency of blood pressure differences between the left and right arms. Arch Intern Med. 2007 Feb 26;167(4):388-93.</citation>
    <PMID>17325301</PMID>
  </reference>
  <reference>
    <citation>Fotherby MD, Panayiotou B, Potter JF. Age-related differences in simultaneous interarm blood pressure measurements. Postgrad Med J. 1993 Mar;69(809):194-6.</citation>
    <PMID>8497433</PMID>
  </reference>
  <reference>
    <citation>Gasowski J, Staessen JA, Celis H, Fagard RH, Thijs L, Birkenhäger WH, Bulpitt CJ, Fletcher AE, Arabidze GG, de Leeuw P, Dollery CT, Duggan J, Kawecka-Jaszcz K, Leonetti G, Nachev C, Safar M, Rodico JL, Rosenfeld J, Seux ML, Tuomilehto J, Webster J, Yodfat Y. Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators. J Hum Hypertens. 1999 Feb;13(2):135-45.</citation>
    <PMID>10100063</PMID>
  </reference>
  <reference>
    <citation>Grucza R, Kahn JF, Cybulski G, Niewiadomski W, Stupnicka E, Nazar K. Cardiovascular and sympatho-adrenal responses to static handgrip performed with one and two hands. Eur J Appl Physiol Occup Physiol. 1989;59(3):184-8.</citation>
    <PMID>2583160</PMID>
  </reference>
  <reference>
    <citation>Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755-62.</citation>
    <PMID>9635947</PMID>
  </reference>
  <reference>
    <citation>Howden R, Lightfoot JT, Brown SJ, Swaine IL. The effects of isometric exercise training on resting blood pressure and orthostatic tolerance in humans. Exp Physiol. 2002 Jul;87(4):507-15.</citation>
    <PMID>12392115</PMID>
  </reference>
  <reference>
    <citation>Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol. 1999 Jun;22(6):385-90.</citation>
    <PMID>10376176</PMID>
  </reference>
  <reference>
    <citation>Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31.</citation>
    <PMID>15207952</PMID>
  </reference>
  <reference>
    <citation>Kelley GA, Kelley KS. Isometric handgrip exercise and resting blood pressure: a meta-analysis of randomized controlled trials. J Hypertens. 2010 Mar;28(3):411-8. doi: 10.1097/HJH.0b013e3283357d16. Erratum in: J Hypertens. 2010 Aug;28(8):1784.</citation>
    <PMID>20009767</PMID>
  </reference>
  <reference>
    <citation>Kerber RE, Miller RA, Najjar SM. Myocardial ischemic effects of isometric, dynamic and combined exercise in coronary artery disease. Chest. 1975 Apr;67(4):388-94.</citation>
    <PMID>1122766</PMID>
  </reference>
  <reference>
    <citation>Lewis SF, Taylor WF, Bastian BC, Graham RM, Pettinger WA, Blomqvist CG. Haemodynamic responses to static and dynamic handgrip before and after autonomic blockade. Clin Sci (Lond). 1983 Jun;64(6):593-9.</citation>
    <PMID>6839666</PMID>
  </reference>
  <reference>
    <citation>McGowan CL, Levy AS, Millar PJ, Guzman JC, Morillo CA, McCartney N, Macdonald MJ. Acute vascular responses to isometric handgrip exercise and effects of training in persons medicated for hypertension. Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1797-802. Epub 2006 Apr 28.</citation>
    <PMID>16648182</PMID>
  </reference>
  <reference>
    <citation>McGowan CL, Visocchi A, Faulkner M, Verduyn R, Rakobowchuk M, Levy AS, McCartney N, MacDonald MJ. Isometric handgrip training improves local flow-mediated dilation in medicated hypertensives. Eur J Appl Physiol. 2007 Feb;99(3):227-34. Epub 2006 Nov 15. Erratum in: Eur J Appl Physiol. 2008 May;103(2):251.</citation>
    <PMID>17106718</PMID>
  </reference>
  <reference>
    <citation>Millar PJ, Bray SR, McGowan CL, MacDonald MJ, McCartney N. Effects of isometric handgrip training among people medicated for hypertension: a multilevel analysis. Blood Press Monit. 2007 Oct;12(5):307-14.</citation>
    <PMID>17890969</PMID>
  </reference>
  <reference>
    <citation>Millar PJ, Bray SR, MacDonald MJ, McCartney N. The hypotensive effects of isometric handgrip training using an inexpensive spring handgrip training device. J Cardiopulm Rehabil Prev. 2008 May-Jun;28(3):203-7. doi: 10.1097/01.HCR.0000320073.66223.a7.</citation>
    <PMID>18496321</PMID>
  </reference>
  <reference>
    <citation>Millar PJ, MacDonald MJ, Bray SR, McCartney N. Isometric handgrip exercise improves acute neurocardiac regulation. Eur J Appl Physiol. 2009 Nov;107(5):509-15. doi: 10.1007/s00421-009-1142-2. Epub 2009 Aug 13.</citation>
    <PMID>19680681</PMID>
  </reference>
  <reference>
    <citation>Millar PJ, MacDonald MJ, McCartney N. Effects of isometric handgrip protocol on blood pressure and neurocardiac modulation. Int J Sports Med. 2011 Mar;32(3):174-80. doi: 10.1055/s-0030-1268473. Epub 2010 Dec 16.</citation>
    <PMID>21165806</PMID>
  </reference>
  <reference>
    <citation>Murakami E, Matsuzaki K, Sumimoto T, Mukai M, Kazatani Y, Kodama K. Clinical significance of pressor responses to laboratory stressor testing in hypertension. Hypertens Res. 1996 Jun;19(2):133-7.</citation>
    <PMID>10968206</PMID>
  </reference>
  <reference>
    <citation>Owen A, Wiles J, Swaine I. Effect of isometric exercise on resting blood pressure: a meta analysis. J Hum Hypertens. 2010 Dec;24(12):796-800. doi: 10.1038/jhh.2010.13. Epub 2010 Feb 25.</citation>
    <PMID>20182455</PMID>
  </reference>
  <reference>
    <citation>Peters PG, Alessio HM, Hagerman AE, Ashton T, Nagy S, Wiley RL. Short-term isometric exercise reduces systolic blood pressure in hypertensive adults: possible role of reactive oxygen species. Int J Cardiol. 2006 Jun 16;110(2):199-205. Epub 2005 Oct 18.</citation>
    <PMID>16239039</PMID>
  </reference>
  <reference>
    <citation>Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005 Feb 8;111(5):697-716.</citation>
    <PMID>15699287</PMID>
  </reference>
  <reference>
    <citation>Ray CA, Carrasco DI. Isometric handgrip training reduces arterial pressure at rest without changes in sympathetic nerve activity. Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H245-9.</citation>
    <PMID>10899063</PMID>
  </reference>
  <reference>
    <citation>Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens. 2000 Oct-Nov;14(10-11):691-704. Review.</citation>
    <PMID>11095160</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10.</citation>
    <PMID>11136953</PMID>
  </reference>
  <reference>
    <citation>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26;265(24):3255-64.</citation>
    <PMID>2046107</PMID>
  </reference>
  <reference>
    <citation>Taylor AC, McCartney N, Kamath MV, Wiley RL. Isometric training lowers resting blood pressure and modulates autonomic control. Med Sci Sports Exerc. 2003 Feb;35(2):251-6.</citation>
    <PMID>12569213</PMID>
  </reference>
  <reference>
    <citation>Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J; National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002 Oct 16;288(15):1882-8.</citation>
    <PMID>12377087</PMID>
  </reference>
  <reference>
    <citation>Badrov MB, Freeman SR, Zokvic MA, Millar PJ, McGowan CL. Isometric exercise training lowers resting blood pressure and improves local brachial artery flow-mediated dilation equally in men and women. Eur J Appl Physiol. 2016 Jul;116(7):1289-96. doi: 10.1007/s00421-016-3366-2. Epub 2016 May 2.</citation>
    <PMID>27137950</PMID>
  </reference>
  <reference>
    <citation>Wiley RL, Dunn CL, Cox RH, Hueppchen NA, Scott MS. Isometric exercise training lowers resting blood pressure. Med Sci Sports Exerc. 1992 Jul;24(7):749-54.</citation>
    <PMID>1501558</PMID>
  </reference>
  <reference>
    <citation>Division of Cardiovascular and Renal Drug Products, Center for Drug Evaluation andResearch (CDER), Food,and Drug Administration. Guidance forIndustry.Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims. 2008.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/ucm075072.pdf</citation>
  </reference>
  <reference>
    <citation>Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002 Oct 1;106(14):1883-92.</citation>
    <PMID>12356646</PMID>
  </reference>
  <reference>
    <citation>Hicks KA, Hung HMJ, Mahaffey KW, et al.</citation>
  </reference>
  <reference>
    <citation>ICH Steering Committee. Draft ICH Consensus Principle:Principles for ClinicalEvaluation ofNew Antihypertensive Drugs. International Conference onHarmonisation ofTechnical Requirements for Registration of Pharmaceuticals forHuman Use. 2000.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073147.pdf</citation>
  </reference>
  <reference>
    <citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. Erratum in: JAMA. 2003 Jul 9;290(2):197.</citation>
    <PMID>12748199</PMID>
  </reference>
  <reference>
    <citation>Kiveloff B, Huber O. Brief maximal isometric exercise in hypertension. J Am Geriatr Soc. 1971 Dec;19(12):1006-12.</citation>
    <PMID>5153689</PMID>
  </reference>
  <reference>
    <citation>Millar, PJ. Isometric handgrip training: a natural hypertensive therapy. TownsendLetter: The Examiner of Alternative Medicine 2008.</citation>
  </reference>
  <reference>
    <citation>Millar PJ, Paashuis A, McCartney. Isometric Handgrip Effects on Hypertension. CurrHypertens Rev 2009;5:54-60</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diastolic</keyword>
  <keyword>Isometric Therapy</keyword>
  <keyword>Prehypertensive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>If in the future Investigators want to access the data for secondary analysis they can submit a for request the central contact. Individual patient data will not be shared , the plan will share aggregate patient data (APD) via 1) final approved clinical study report 2) any manuscripts or summary results report via an email request to the central contact once database lock has occurred and reports are generated.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

